Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

249 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immunogenicity and safety of SARS-CoV-2 recombinant protein vaccine (CHO cell) LYB001 as a heterologous booster following two- or three-dose inactivated COVID-19 vaccine in adults aged ≥18 years: interim results of a randomized, active-controlled, double-blinded, phase 3 trial.
Yang BF, Jin J, He XR, Yang ZH, Qian X, Tong YQ, Ke CX, Li ZH, Li ZX, Zhong LF, Gan ZH, Zhang XF, Zeng Y. Yang BF, et al. Expert Rev Vaccines. 2025 Dec;24(1):81-90. doi: 10.1080/14760584.2024.2446288. Epub 2025 Jan 5. Expert Rev Vaccines. 2025. PMID: 39720838 Free article. Clinical Trial.
Immunogenicity and safety of an enterovirus 71 vaccine in children aged 36-71 months: A double-blind, randomised, similar vaccine-controlled, non-inferiority phase III trial.
Tong Y, Zhang X, Chen J, Chen W, Wang Z, Li Q, Duan K, Wei S, Yang B, Qian X, Li J, Hang L, Deng S, Li X, Guo C, Shen H, Liu Y, Deng P, Xie T, Li Q, Li L, Du H, Mao Q, Gao F, Lu W, Guan X, Huang J, Li X, Chen X. Tong Y, et al. EClinicalMedicine. 2022 Jul 29;52:101596. doi: 10.1016/j.eclinm.2022.101596. eCollection 2022 Oct. EClinicalMedicine. 2022. PMID: 35923425 Free PMC article.
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial.
Zhu FC, Guan XH, Li YH, Huang JY, Jiang T, Hou LH, Li JX, Yang BF, Wang L, Wang WJ, Wu SP, Wang Z, Wu XH, Xu JJ, Zhang Z, Jia SY, Wang BS, Hu Y, Liu JJ, Zhang J, Qian XA, Li Q, Pan HX, Jiang HD, Deng P, Gou JB, Wang XW, Wang XH, Chen W. Zhu FC, et al. Among authors: yang bf. Lancet. 2020 Aug 15;396(10249):479-488. doi: 10.1016/S0140-6736(20)31605-6. Epub 2020 Jul 20. Lancet. 2020. PMID: 32702299 Free PMC article. Clinical Trial.
Immunogenicity and safety of purified vero cell-cultured rabies vaccine under Zagreb 2-1-1 or 5-dose Essen regimen in the healthy Chinese subjects: a randomized, double-blind, positive controlled phase 3 clinical trial.
Shen H, Wang Z, Yang B, Cai K, Jiang C, Xie R, Xiao H, Ren Q, Qi Z, Li J, Li Q, Ye J, Zhan F. Shen H, et al. Hum Vaccin Immunother. 2021 Feb 1;17(2):351-357. doi: 10.1080/21645515.2020.1778408. Epub 2020 Aug 12. Hum Vaccin Immunother. 2021. PMID: 32783769 Free PMC article. Clinical Trial.
Immunogenicity and Safety of an F-Genotype Attenuated Mumps Vaccine in Healthy 8- to 24-Month-Old Children.
Liang Y, Che Y, Yang B, Zhan F, Li H, Guan X, Zhang Y, Yin Q, Li C, Li J, Zhao Z, Liu L, Jiang G, Liao Y, Xu X, Ye J, Ren Q, He Y, Feng M, Wang L, Fan S, Cui X, Wang Z, Li C, Xiao H, Liu R, Li Q, Jiang C, Liu J, Li Q. Liang Y, et al. J Infect Dis. 2019 Jan 1;219(1):50-58. doi: 10.1093/infdis/jiy469. J Infect Dis. 2019. PMID: 30085178 Clinical Trial.
249 results